Endocrinology Flashcards
diagnosis for diabetes made by ONE of the following (4 different ways)
- 2 FASTING glucose greater than or equal to 126
- ONE RANDOM glucose greater than or equal to 200 WITH symptoms (polyuria, polydipsia, polyphagia)
- ABNORMAL GTT (2-hour GTT with 75G glucose load)
- HbA1c greater than 6.5%
STRONGEST indication for screening for diabetes
HTN
mechanism for type 2 diabetes
excess fat = insulin deficiency
best INITIAL treatment for type 2 diabetes
- DIET
- EXERCISE
- WEIGHT LOSS
best INITIAL MEDICAL treatment for type 2 diabetes
metformin (biguanide)
metformin MOA
blocks gluconeogenesis
main advantages of metformin (2)
- no risk of hypOglycemia
- does NOT increase obesity
metformin CONTRAindications (2 main ones)
- renal insufficiency
- use of contrast
name the sulfonylureas (3)
- glyburide
- glimepiride
- glipizide
sulfonylurea MOA
increase insulin RELEASE from pancreas
sulfonylurea ADVERSE EFFECTS (2 main ones)
- hypOglycemia
- SIADH
name the dipeptidyl peptidase 4 (DPP-4) inhibitors
- sitaGLIPTIN
- linaGLIPTIN
- aloGLIPTIN
- saxaGLIPTIN
dipeptidyl peptidase 4 (DPP-4) inhibitor MOA
block metabolism of INCRETINS
mechanism of incretins (GLP and GIP)
```
GLP = glucagon-like peptide
(GIP = glucose insulinotropic peptide)
~~~
increase insulin and decrease glucagon secretion from pancreas
name the thiazolidinediones
- rosiGLITAZONE
- pioGLITAZONE
thiazolidinedione MOA
increase PERIPHERAL insulin sensitivity
thiazolidinediones CONTRAindication
CHF
name the a-glucosidase inhibitors
- acarbose
- miglitol
a-glucosidase inhibitor MOA
block glucose ABSORPTION in intestinal lining
name the insulin secretagogues
- nateGLINIDE
- repaGLINIDE
secretagogue MOA
increase insulin RELEASE from pancreas
name the SGLT inhibitors (sodium-glucose transport)
- canaGLIFLOZIN
- dapaGLIFLOZIN
- empaGLIFLOZIN
SGLT inhibitor MOA
inhibits glucose reabsorption in kidneys
name the GLP (glucagon insulinotropic peptide) analogs
- exenaTIDE
- liragluTIDE